GSK gets EC approval for new administration options of asthma treatment Nucala
This article was originally published here
Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma
The post GSK gets EC approval for new administration options of asthma treatment Nucala appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!